Login / Signup
Albert Bosch Vilaro
ORCID
Publication Activity (10 Years)
Years Active: 2024-2024
Publications (10 Years): 5
Top Topics
Clinical Trial
Gestational Age
Mesenchymal Stem Cells
High Intensity
Top Venues
Dermatology and therapy
</>
This page only lists publications with an associated author ORCID identifier.
Publications
</>
Tiago Torres
,
Anne Sohrt
,
Ulla Ivens
,
Albert Bosch Vilaro
,
John Stinson
,
Y José Manuel Carrascosa
Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis.
Dermatology and therapy
14 (4) (2024)
Tiago Torres
,
Anne Sohrt
,
Ulla Ivens
,
Albert Bosch Vilaro
,
John Stinson
,
Y José Manuel Carrascosa
Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis.
Dermatology and therapy
14 (4) (2024)
Tiago Torres
,
Anne Sohrt
,
Ulla Ivens
,
Albert Bosch Vilaro
,
John Stinson
,
Y José Manuel Carrascosa
Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis.
Dermatology and therapy
14 (4) (2024)
Tiago Torres
,
Anne Sohrt
,
Ulla Ivens
,
Albert Bosch Vilaro
,
John Stinson
,
Y José Manuel Carrascosa
Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis.
Dermatology and therapy
(2024)
Tiago Torres
,
Anne Sohrt
,
Ulla Ivens
,
Albert Bosch Vilaro
,
John Stinson
,
Y José Manuel Carrascosa
Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis.
Dermatology and therapy
14 (4) (2024)